Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Pier 88 Investment Partners LLC

Pier 88 Investment Partners LLC cut its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 86.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 170,890 shares of the company’s stock after selling 1,052,550 shares during the period. Pier 88 Investment Partners LLC’s holdings in Health Catalyst were worth $1,208,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Impax Asset Management Group plc increased its position in Health Catalyst by 7.7% during the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after purchasing an additional 195,525 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after acquiring an additional 66,896 shares in the last quarter. State Street Corp lifted its holdings in shares of Health Catalyst by 2.5% during the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock valued at $9,473,000 after acquiring an additional 28,251 shares in the last quarter. Fred Alger Management LLC purchased a new stake in Health Catalyst during the 3rd quarter worth $6,858,000. Finally, American Century Companies Inc. increased its holdings in Health Catalyst by 1.8% in the 4th quarter. American Century Companies Inc. now owns 710,481 shares of the company’s stock valued at $5,023,000 after purchasing an additional 12,682 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Stock Performance

Shares of Health Catalyst stock opened at $4.55 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst, Inc. has a 1 year low of $3.76 and a 1 year high of $9.24. The firm’s 50-day simple moving average is $5.03 and its 200-day simple moving average is $6.85. The firm has a market cap of $319.46 million, a PE ratio of -3.37 and a beta of 1.41.

Insider Activity at Health Catalyst

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of Health Catalyst stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares of the company’s stock, valued at $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the sale, the chief operating officer now directly owns 91,253 shares in the company, valued at $685,310.03. This trade represents a 5.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,530 shares of company stock valued at $299,572 over the last three months. 2.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HCAT shares. Canaccord Genuity Group decreased their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Stifel Nicolaus lowered their price objective on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a research report on Thursday, February 27th. Piper Sandler reduced their target price on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a report on Wednesday, January 8th. Finally, Royal Bank of Canada cut their price objective on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.27.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.